Lisata Therapeutics, Inc. reported a net loss of $16.6 million for the fiscal year ending December 31, 2025, a decrease from the $20.0 million loss recorded in the previous year. The company's revenue for 2025 was $0.2 million, down from $1.0 million in 2024, primarily due to the conclusion of the Exclusive License and Collaboration Agreement with Kuva Labs, Inc. Operating expenses also decreased to $18.4 million from $23.4 million, reflecting a reduction in research and development costs and general administrative expenses. The company attributed the decrease in operating expenses to staff reductions and lower spending on clinical trials.
In a significant strategic development, Lisata announced a proposed acquisition by Kuva Labs, Inc. on March 6, 2026. Under the terms of the merger agreement, Kuva will offer $5.00 per share in cash for all outstanding shares of Lisata, along with a contingent value right that could yield an additional $1.00 per share if certain regulatory milestones are met. The merger is expected to close in the second quarter of 2026, subject to customary closing conditions. If completed, Lisata will become a wholly-owned subsidiary of Kuva, and its common stock will be delisted from the Nasdaq Capital Market.
Lisata's operational metrics indicate a lean workforce, with 21 full-time employees as of December 31, 2025. The company has focused on advancing its investigational product, certepetide, which is designed to enhance the delivery of anti-cancer therapies to solid tumors. Certepetide has been the subject of multiple Phase 2 clinical trials across various solid tumor types, including pancreatic cancer. The company continues to explore partnerships to leverage its CendR Platform® for potential collaborations in the oncology space.
The company faces substantial financial challenges, with cash and cash equivalents totaling approximately $16.0 million as of December 31, 2025. Management has expressed substantial doubt regarding its ability to continue as a going concern without raising additional capital. The company plans to pursue various funding avenues, including equity offerings and potential collaborations, to support its ongoing operations and clinical development programs. However, there is no assurance that Lisata will be able to secure the necessary funding on favorable terms, which could significantly impact its business operations and future prospects.
About LISATA THERAPEUTICS, INC.
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for solid tumors and major diseases. Its lead investigational drug, certepetide, enhances delivery and efficacy of anti-cancer treatments by activating a tumor-specific transport pathway. The company targets cancers like pancreatic ductal adenocarcinoma, leveraging its proprietary CendR platform to improve treatment outcomes through combination therapies and collaborations.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.